- Previous Close
92.46 - Open
92.19 - Bid 91.90 x 100
- Ask 92.07 x 100
- Day's Range
91.45 - 93.17 - 52 Week Range
75.93 - 104.07 - Volume
315,941 - Avg. Volume
1,053,736 - Market Cap (intraday)
18.317B - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
54.11 - EPS (TTM)
1.70 - Earnings Date Aug 28, 2024 - Sep 2, 2024
- Forward Dividend & Yield 0.02 (0.02%)
- Ex-Dividend Date Jul 26, 2023
- 1y Target Est
108.29
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including endosee endometrial imaging products, fetal pillow cephalic elevation devices for use in cesarean sections, illuminated speculum products, lone star retractor systems, loop electrosurgical excision procedure products, mara water ablation systems, paragard contraceptive IUDs, point-of-care, and uterine positioning products, as well as cryostorage, such as cord blood and cord tissue storage; fertility products and services, such as fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
www.coopercos.com15,000
Full Time Employees
October 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: COO
Performance Overview: COO
Trailing total returns as of 6/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COO
Valuation Measures
Market Cap
18.41B
Enterprise Value
21.01B
Trailing P/E
54.47
Forward P/E
25.91
PEG Ratio (5yr expected)
10.59
Price/Sales (ttm)
4.95
Price/Book (mrq)
2.36
Enterprise Value/Revenue
5.63
Enterprise Value/EBITDA
21.67
Financial Highlights
Profitability and Income Statement
Profit Margin
9.11%
Return on Assets (ttm)
3.21%
Return on Equity (ttm)
4.48%
Revenue (ttm)
3.73B
Net Income Avi to Common (ttm)
339.9M
Diluted EPS (ttm)
1.70
Balance Sheet and Cash Flow
Total Cash (mrq)
112.4M
Total Debt/Equity (mrq)
38.33%
Levered Free Cash Flow (ttm)
111.38M